Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

682

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza Immunization

Interventions

BIOLOGICAL: Quadrivalent Influenza mRNA Vaccine MRT5410
BIOLOGICAL: Quadrivalent Recombinant Influenza vaccine RIV4
BIOLOGICAL: Quadrivalent Inactivated Influenza Standard Dose QIV-SD
BIOLOGICAL: Quadrivalent Inactivated Influenza High Dose QIV-HD

Sponsor

Sanofi Pasteur, a Sanofi Company